Head-to-head · WeighScore
SkinnyRx vs TeleDocs360
By GLP-1 ScorecardUpdated
Score comparison
SkinnyRx has the higher recorded score — 60.5/100 to 55.2/100.
SkinnyRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Publishes four introductory compounded-treatment offers, but continuing costs, usable supply and the interaction between cancellation and refund rules need confirmation.
Before you choose
Before comparing the headline prices, the SkinnyRx review and the TeleDocs360 review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, SkinnyRx vs telos rx and TeleDocs360 vs Tru2u compare each of them with another graded program, and the list of alternatives to SkinnyRx ranks the programs closest to SkinnyRx on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | SkinnyRx | TeleDocs360 |
|---|---|---|
| WeighScore | 60.5/100 | 55.2/100 |
| Grade | C | C |
| Site position | #274 | #473 |
| Semaglutide | Injection advertised $99 first month; compounded tablets $149 first month. Confirm the recurring price, selected term and usable prescription supply. | $229/mo month-to-month ($189/mo on 3-month plan; compounded) |
| Tirzepatide | Injection advertised $99 first month; compounded dissolving tablets $199 first month. Confirm the recurring price, selected term and usable prescription supply. | $349/mo month-to-month ($299/mo on 3-month plan; compounded) |
| Coverage | Current terms exclude certain compounded offerings in Alabama, Louisiana and Mississippi; confirm eligibility for the exact route and pharmacy. | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #274 · C
FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.
Strengths
- Advertises separate first-month prices for both compounded molecules and both injection and tablet routes
- Current terms describe the ninety-day commercial guarantee’s dose logging, claim-window, promotional eligibility and coverage requirements
- Names a medical director/advisor in public information; this does not identify the assigned treating professional
- Publishes compounded-treatment state exclusions and cancellation channels rather than leaving every operational detail unspecified
What to consider
- First-month prices do not establish the recurring amount, selected full prepayment or usable medication quantity
- Cancellation requires five days’ notice before renewal processing, which can itself precede the next subscription period
- The guarantee’s bundled-refund language needs clarification alongside general third-party-fee deductions, medication-return requirements and product FAQ restrictions
- Microdose badges and daily tablet descriptions do not establish a separate price, complete prescription or equivalent branded-treatment results
- The actual prescribing practice, assigned clinician, dispensing pharmacy, physical compounder and patient-lab costs remain unconfirmed
- The named advisor’s Florida record flags discipline and a public complaint, while Oregon lists a surrendered license; neither record determines every clinician’s authority or the patient assignment
- FDA issued Lean Rx Inc. dba SkinnyRx a warning letter on February 20, 2026; website testing claims do not establish independent pharmacy verification.
Strengths
- Published standard-dose pricing: $229/mo semaglutide and $349/mo tirzepatide month-to-month, lower on 3-month plans
- Multiple GLP-1 options including injectable and oral semaglutide
- Cash-pay model with HSA/FSA card acceptance
- Fast online intake and 24-hour prescription approval
- Cancel anytime between shipments
What to consider
- Compounded-only; no FDA-approved branded options
- No published state availability list
- No individual provider credentials or board certifications shown
- Higher doses increase cost
Featured provider
SkinnyRx
SkinnyRx scores 60.5/100 (C). Publishes four introductory compounded-treatment offers, but continuing costs, usable supply and the interaction between cancellation and refund rules need confirmation.
Commercial relationships affect this placement. The score comparison above is separate.
FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.